Matthew Nock
Professor of Psychology
Data updated
Research Footprint
Matthew Nock appears in 9 tracked papers (2019–2023), most studied alongside Psilocybin, LSD and Mescaline, across Substance Use Disorders (SUD), Suicidality and Public Health, Prevention & Behaviour Change.
Most-cited paper: Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial (178 citations).
Frequent co-authors: George Jones, Daniel Ionescu and Maurizio Fava.
Background & Research
Matthew K. Nock is Professor of Psychology at Harvard University and a senior clinical-scientist whose primary career contributions have been in the epidemiology, measurement and prediction of suicide, self-injury and related psychopathology. Over the past several years he has extended his methodological expertise to population-level investigations of psychedelic exposures, co-authoring multiple large nationally representative survey analyses that examine associations between lifetime use of classic psychedelics (including psilocybin and LSD), MDMA/ecstasy and a range of outcomes such as major depressive episodes, nicotine dependence, opioid and cocaine use disorders, and criminal-justice involvement.
Nock's work in psychedelic science is characterised by careful attention to sampling, confounding control and moderation (notably by race and ethnicity), and by situating observational findings within broader clinical and public-health contexts. He has emphasised statistical rigour and transparency in analyses of substance-use and mental-health correlates of psychedelic use. Disclosure: Nock receives publication royalties from Macmillan, Pearson and UpToDate.
Key Impact
Notable for applying rigorous, large-scale epidemiological and survey methods to characterise associations between lifetime psychedelic use and mental-health and substance-use outcomes.
Collaboration Network
3 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Matthew Nock is associated with.
Harvard University
Non-ProfitHarvard University hosts multiple psychedelic research initiatives including the Study of Psychedelics in Society and Culture (a $16M program), the MGH Center for the Neuroscience of Psychedelics, and the Harvard Law School POPLAR project addressing psychedelic policy reform. These programs span neuroscience, cultural studies, and legal advocacy to advance scientific and societal understanding of psychedelics.
View stakeholder →Massachusetts General Hospital
hospitalThe Center for the Neuroscience of Psychedelics aims to better understand how psychedelics can be used to improve the treatment of mental illnesses. The core mission of the center is to understand exactly how psychedelics enhance the brain's capacity for change—or neuroplasticity—to optimize current treatments and render the term treatment resistant obsolete.
View stakeholder →